Abstract
Non-pharmaceutical interventions (NPIs) implemented to contain SARS-CoV-2 have decreased invasive pneumococcal disease. We undertook an observational study to evaluate the impact of NPIs on pneumococcal carriage and density, drivers of transmission and disease, during the COVID-19 pandemic in Ho Chi Minh City, Vietnam. While NPIs did not significantly impact pneumococcal carriage, mean capsular pneumococcal density decreased by up to 91.5% (1.07 log10genome equivalents/mL, 95% Confidence Interval: 0.74-1.41) after NPI introduction compared with the pre-COVID-19 period. As higher pneumococcal density is a risk factor for disease, the observed decline provides a plausible mechanism for the reductions in invasive pneumococcal disease.
Competing Interest Statement
CS is a lead investigator, and KM and CN are co-investigators, on a Merck Investigator Studies Program grant funded by MSD outside of this work. KM is a lead investigator, and CS and CN are co-investigators, on a Pfizer funded study outside of this work. CN is on a Data Safety Monitoring Board outside of this work (no payment). JB prepared a report on pneumococcal serotypes for MSD outside of this work. JH receives project grants from Pfizer that are outside of this work, and is a co-founder and board member of BUGS Bioscience Ltd., a not-for-profit spin-out company (no personal payment). KM is a member of WHO SAGE committee (no payment) and KM and CS are Board members of ISPPD (no payment). None of the other authors have any competing interests to declare.
Funding Statement
The vaccine trial was supported by the Bill & Melinda Gates Foundation (grant number OPP-1116833/INV-008627). We also acknowledge the Victorian Governments Operational Infrastructure Support Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained for the vaccine trial from the Human Research Ethics Committee of the Royal Childrens Hospital Melbourne, the Institutional Review Board at the Pasteur Institute of Ho Chi Minh City, and the Vietnam Ministry of Health Ethical Review Committee for Biomedical Research. The vaccine trial is registered at clinicaltrials.gov (NCT03098628).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Deidentified data are available upon reasonable request. Requests must be compliant with the vaccine trial ethical approvals. Requests should be directed to Professor Kim Mulholland (https://orcid.org/0000-0001-7947-680X).
